A case of carbapenemase-producing Klebsiella pneumoniae in Australia

Pathology

Volumn 44, Issue 1, 2012, Pages 42-44

  Coatsworth, Nicholas R ^a   Huntington, Peter G ^a   Hardiman, Robyn P ^a   Hudson, Bernard J ^a   Fernandes, Clarence J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858262543     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32834e4228     Document Type: Article

References (14)

1. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S20. Vol. 30, no. 1. Wayne, PA: CLSI, 2010.
2. Tsakris A, Poulou A, Pournaras S, et al. A simple phenotypic method for the differentiation of metallo-b-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. J Antimicrob Chemother 2010; 65: 1664-71.
3. US Food and Drug Administration. Tygacil (tigecycline) iv injection label. Revised July 2010 (cited 8 Nov 2010). http://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/021821s027lbl.pdf.
4. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City. Arch Intern Med 2005; 165: 1430-5.
5. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing b-lactamase KPC-1 from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45: 1151-61. (Pubitemid 32230996)
6. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9: 228-36.
7. Naas T, Nordmann P, Vedel G, et al. Plasmid-mediated carbapenemhydrolyzing b-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 2005; 49: 4423-4. (Pubitemid 41401006)
8. Fernando G, Collignon P, Bell J. A risk for returned travellers: The 'postantibiotic era'. Med J Aust 2010; 193: 59.
9. Kontopoulou K, Protonotariou E, Vasilakos K, et al. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 b-lactamase resistant to colistin. J Hosp Infect 2010; 76: 70-3.
10. Marchaim D, Navon-Venzia S, Schwaber MJ, et al. Isolation of imipenemresistant Enterobacter species; emergence of KPC-carbapenemase, molecular characterization, epidemiology and outcomes. Antimicrob Agents Chemother 2008; 52: 1413-8. (Pubitemid 351522007)
11. Daly MW, Riddle DJ, Ledeboer NA, et al. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 2007; 27: 1052-7. (Pubitemid 46986692)
12. Elemam A, Rahimian J, Doymaz M. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol 2010; 48: 3558-62.
13. Michalopoulos A, Virtzili S, Rafailidis P, et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: A prospective evaluation. Clin Microbiol Infect 2010; 16: 184-6.
14. Pournaras S, Protonotariou E, Voulgari E, et al. Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece. J Antimicrob Chemother 2009; 64: 348-52.